What does the research say about Therapy-related acute myeloid leukemia?

Therapy-related acute myeloid leukemia

There are 2 papers on therapy-related acute myeloid leukemia in aging research: 1 observational study in people.

2 papers study it4 findings

“which PPM1D was more frequently associated with therapy-related AML (t-AML).”

Venetoclax + azacitidine

downin humans1

1 study

Venetoclax + azacitidine is linked with lower therapy-related acute myeloid leukemia in humans after CAR-T-associated therapy-related AML (partial remission).
“The patient received azacitidine plus venetoclax, achieving partial remission”
Humansafter CAR-T-associated therapy-related AMLmales
Therapy-related acute myeloid leukemia with 24-month latency after CD19 CAR-T cell therapy in relapsed/refractory diffuse large B-cell lymphoma: a case report
Frontiers in medicineAug 14, 2026

TP53

upin humans1

1 study

TP53 is associated with therapy-related acute myeloid leukemia in humans (biallelic loss (copy number loss and p.P278A point mutation) acquired after CAR-T therapy).
“longitudinal genomic monitoring demonstrating evolution from wild-type TP53 to biallelic TP53 loss”
Humansbiallelic loss (copy number loss and p.P278A point mutation) acquired after CAR-T therapymales
Therapy-related acute myeloid leukemia with 24-month latency after CD19 CAR-T cell therapy in relapsed/refractory diffuse large B-cell lymphoma: a case report
Frontiers in medicineAug 14, 2026